| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |